PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunityNeus Martínez‐Bosch(Hospital Del Mar), Pilar Navarro(Consejo Superior de Investigaciones Científicas)Science AdvancesMay 8, 202610.1126/sciadv.adu8849Cited by 0SaveCiteExport RISWatch citationsRelated PapersTissue Plasminogen Activator Induces Pancreatic Cancer Cell Proliferation by a Non-Catalytic Mechanism That Requires Extracellular Signal-Regulated Kinase 1/2 Activation through Epidermal Growth Factor Receptor and Annexin A2|American Journal Of Pathology|2007|76The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer|Oncotarget|2016|11